Aquinox sets terms for $41M IPO; Compugen shares plunge; Actelion wins fast-track status

@FierceBiotech: GlaxoSmithKline hits the brakes on an anti-inflammatory drug from Galapagos. News | Follow @FierceBiotech

@JohnCFierce: Remember that big Gilead bet on Pharmasset? It paid off and made John Martin a billionaire. Item | Follow @JohnCFierce

@DamianFierce: India's Lupin queues up for a share of the biosimilar boom. Story | Follow @DamianFierce

@EmilyMFierce: Experimental supplement extends lifespan, stops metabolic disease in mice. Article from FierceBiotechResearch | Follow @EmilyMFierce

> Aquinox Pharmaceuticals has set its terms for a $41 million IPO, looking to seal shares at $10 to $12 a share. Story

> Shares of Israel's Compugen ($CGEN) plunged after it sold stock at a discount. Report

> Actelion ($ATLN) says the FDA has granted fast-track status for its diarrhea therapy. Story

> Cell Therapeutics ($CTIC) has launched a Phase III clinical trial, PERSIST-2, to study pacritinib in patients with myelofibrosis. Release

Medical Device News

@FierceMedDev: How to gain new stent sales in a sluggish market: bulk discount deals. Story | Follow @FierceMedDev

@MarkHFierce: For Covidien, a ventilation system wins a CE mark after other product setbacks in the space. More | Follow @MarkHFierce

@MichaelGFierce: New manufacturing technique offers tailored delivery nanoparticles made of iron, silver and silicon. Article from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: White noise sleep machines at full volume could cause hearing damage in infants, say researchers. News | Follow @EmilyWFierce

> Abbott and Medtronic are sharing a bulk discount deal to sell stents at 135 hospitals. More

> GE Ventures pours cash into RainDance's $16.5M Series E extension. Story

> BSD bets on new ablation device sales growth in its ongoing Terumo deal. More

Pharma News

@FiercePharma: Best-read over the weekend: Pradaxa, Xarelto makers dispute purported Eliquis safety edge. Piece | Follow @FiercePharma

@TracyStaton: The graph's the thing: Takeda admits to 'inappropriate' drug advertising in Japan. News (sub. req.) | Follow @TracyStaton

@EricPFierce: WSJ says Pfizer angling for OTC Lipitor. That will get generic drugmakers' notice. Story | Follow @EricPFierce

@CarlyHFierce: Teva's new Copaxone formula could be a hard sell with payers. Article | Follow @CarlyHFierce

> Questcor, short sellers trade attacks. More

> No merger talk here: Novartis just wants to be friends with Roche, chairman says. Story

> Generic makers to FDA: Labeling rule risky for patients, adds $4B in annual costs. News

CRO News

> InVentiv amps up its biosimilar efforts with latest deal. Story

> Report: VC giant Sequoia unloading $50M stake in India's GVK. News

> Quintiles touts its talent as cash rolls in. Article

> Cardialysis taps AG Mednet to handle an ocean of trial data. Story

> MPI's imaging team-up snags a cyclotron as it preps for opening day. Story

> Charles River looks to Exostar for cloud-based data platform. Brief

Biotech IT News

> Google joins genomics alliance as it prepares industry-focused cloud services. News

> Novartis' pitch to join trial data sharing bandwagon gets frosty reception. Story

> U.K. begins trying to rebuild trust in patient database after months of 'confusion, suspicion and anxiety.' Article

> FDA defends itself against accusations its email snooping broke whistleblower laws. Story

> George Washington University to trial 40-Gbps genomics data transfers with NIH. Article

> NIH adds genetic data from Kaiser, UCSF to online resource. Brief

 

Suggested Articles

It’s been a good year for Intellia: One of its founders, Jennifer Doudna, Ph.D., nabbed the Nobel Prize in Chemistry for her CRISPR research.

After stints at Eli Lilly, Boehringer Ingelheim and Bristol Myers Squibb, Sid Kerkar, M.D., is hopping over to a small biotech.

Two long noncoding RNAs called TROLL-2 and TROLL-3 influence protein signaling to drive the progression of breast cancer, a new study revealed.